LEXICON
No.152 March 4, 2016

Special expansion re-pricing (Huge-seller re-pricing)
特例拡大再算定(巨額再算定)

The Ministry of Health, Labor and Welfare (MHLW) will introduce in April 2016 a special expansion re-pricing rule (特例拡大再算定; tokurei kakudai sai santei ), dubbed a “huge-seller” re-pricing rule (巨額再算定; kyogaku sai santei ), which it describes as an extraordinary...

To read the full story

LEXICON

By Yoshinori Sagehashi

As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…

By Reiji Anasako

Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…

By Takashi Ohama

An adult man who completed the administration of an investigational drug in a Japan PI study conducted by Eisai has died. Whether there was a causal relationship between the drug and the subject’s death remains unclear at the present time,…

By Reiji Anasako

Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Philip Carrigan

Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…